TOPIC
DETAIL
CLINICAL RELEVANCE
DRUG OR TEST
gp120 binds CD4, then CCR5 (macrophage-tropic) or CXCR4 (T-cell-tropic)
CCR5 Δ32 homozygotes protected
Maraviroc (CCR5 antagonist) · tropism assay first
gp41 drives membrane fusion
—
Enfuvirtide
RT (error-prone) makes dsDNA from RNA
High mutation rate → resistance
NRTIs, NNRTIs
Integrase inserts proviral DNA into host genome
Latent reservoir in resting memory T cells → no cure
Integrase inhibitors (-tegravir)
Protease cleaves gag-pol polyprotein
Immature virions not infectious
Protease inhibitors (-navir)
tat (transcription), rev (RNA export), nef (↓ MHC I), vpu, vif (blocks APOBEC3G)
Immune evasion
—
Sex (anal receptive highest), needles, perinatal, breast milk, transfusion
Risk ↑ with high viral load and genital ulcers
PrEP (tenofovir-based, cabotegravir) · PEP within 72 h for 28 days
4th-gen antigen/antibody immunoassay (p24 appears ~2 weeks)
Shorter window than antibody-only tests
Screen everyone 15–65 at least once
HIV-1/HIV-2 antibody differentiation immunoassay; HIV RNA (NAT) if negative/indeterminate
Western blot no longer used
—
Maternal IgG present up to 18 months
Antibody tests falsely ⁺
HIV DNA/RNA PCR
Acute retroviral syndrome
2–4 weeks post-exposure; very high viral load
Mono-like: fever, pharyngitis, lymphadenopathy, rash, oral ulcers
Antibody may be negative → HIV RNA
Viral set point; ongoing replication in lymph nodes; CD4 falls ~50–100/year
Generalized lymphadenopathy, few symptoms
Start ART for everyone at diagnosis
CD4 < 200/µL or AIDS-defining illness
Opportunistic infections, cancers, wasting, dementia
Viral load (treatment response) and CD4 (immune status, prophylaxis)
Goal: undetectable load → no sexual transmission
Genotype resistance testing before ART